Abbott (ABT) → Stock, financial statements


113.24 USD +1.20 (+0.94%)
May 20 🇺🇸 NYSE ABT
Dividends News
  • ABT Ticker
  • 🇺🇸 NYSE Exchange
  • 103,000 Employees
29 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon

Financial statements — Abbott

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
35B 32B 31B 27B 21B
Cost Of Revenue
15B 13B 13B 12B 9B
Gross Profit
20B 19B 18B 15B 12B
Research and Development
2.4B 2.4B 2.3B 2.2B 1.4B
Selling General and Admin
9.7B 9.8B 9.7B 9.1B 6.7B
Operating Expense
29B 27B 27B 26B 18B
Operating Income
5.4B 4.5B 3.7B 1.7B 3.2B
Other Income Expense Net
0 0 0 0 0
5.4B 4.5B 3.7B 1.7B 3.2B
Interest Income
500M 580M 720M 780M 330M
Pretax Income
5B 4.1B 2.9B 2.2B 1.4B
Income Tax
500M 390M 540M 1.9B 350M
Minority Interest
0 0 0 0 0
Net Income
4.5B 3.7B 2.4B 480M 1.4B
Net Income Basic
4.5B 3.7B 2.4B 480M 1.4B
20 ← 16 2020 2019 2018 2017 2016
Current cash
7.1B 4.1B 4.1B 9.6B 19B
Short term investments
1.9B 1.8B 1.6B 1.7B 1.8B
6.4B 5.4B 5.2B 5.2B 3.2B
5B 4.3B 3.8B 3.6B 2.4B
Other current assets
1.9B 1.8B 1.6B 1.7B 1.8B
Current assets
20B 16B 15B 20B 27B
Long term investments
52B 52B 53B 56B 26B
Property plant equipment
9B 8B 7.6B 7.6B 5.7B
24B 23B 23B 24B 7.7B
Intangible assets
15B 17B 19B 21B 4.5B
Other assets
3.5B 3.1B 1.9B 1.9B 2.3B
Total assets
73B 68B 67B 76B 53B
Accounts payable
3.9B 3.3B 3B 2.4B 1.2B
Current long term debt
220M 1.5B 210M 710M 1.3B
Other current liabilities
7.7B 6.1B 5.8B 5.8B 4.2B
Total current liabilities
12B 11B 9B 8.9B 6.7B
Long term debt
19B 17B 19B 27B 21B
Other liabilities
6.8B 6.8B 6B 7B 4.2B
Minority Interest
220M 210M 200M 200M 180M
Total Liabilities
40B 37B 37B 45B 32B
Common stock
1.8B 1.8B 1.8B 1.7B 1.5B
Retained earning
28B 26B 25B 24B 26B
Treasury stock
-10B -10B -10B -10B -11B
Capital surplus
Shareholder equity
33B 31B 31B 31B 21B
Net tangible assets
-5.7B -9.1B -12B -15B 8.3B
20 ← 16 2020 2019 2018 2017 2016
Net Income
4.5B 3.7B 2.4B 480M 1.4B
3.3B 3B 3.3B 3B 1.4B
Changes in receivables
990M 240M -67M 2B -170M
Changes in inventories
700M 520M 200M 1.2B -170M
Cash change
3B 54M -5.5B -9.2B 13B
Cash flow
7.9B 6.1B 6.3B 5.6B 3.2B
Capital expenditures
-2.2B -1.6B -1.4B -1.1B -1.1B
Investing activity other
Total investing cash flows
-2.2B -1.8B -1.4B -9.6B -250M
Dividends paid
Net borrowings
9.7B 12B 14B 17B 1.4B
Other financing cash flows
Cash flow financing
-2.8B -4.3B -10B -5.3B 11B
Exchange rate effect

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.